These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 29136030)
1. Prospects for passive immunity to prevent HIV infection. Morris L; Mkhize NN PLoS Med; 2017 Nov; 14(11):e1002436. PubMed ID: 29136030 [TBL] [Abstract][Full Text] [Related]
2. Insights from HIV-1 vaccine and passive immunization efficacy trials. Ahmed S; Herschhorn A Trends Mol Med; 2024 Oct; 30(10):908-912. PubMed ID: 38890027 [TBL] [Abstract][Full Text] [Related]
3. In vivo protection by broadly neutralizing HIV antibodies. van Gils MJ; Sanders RW Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020 [TBL] [Abstract][Full Text] [Related]
4. Qualitative and quantitative variables that affect the potency of Fc- mediated effector function in vitro and in vivo: considerations for passive immunization using non-neutralizing antibodies. Lewis GK Curr HIV Res; 2013 Jul; 11(5):354-64. PubMed ID: 24191940 [TBL] [Abstract][Full Text] [Related]
5. Broadly neutralizing antibodies against HIV-1: templates for a vaccine. van Gils MJ; Sanders RW Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615 [TBL] [Abstract][Full Text] [Related]
6. Model for competition from self during passive immunization, with application to broadly neutralizing antibodies for HIV. Ali Tabei SM; Li Y; Weigert M; Dinner AR Vaccine; 2012 Jan; 30(3):607-13. PubMed ID: 22119591 [TBL] [Abstract][Full Text] [Related]
8. Neutralizing antibodies take a swipe at HIV in vivo. Montefiori DC Nat Med; 2005 Jun; 11(6):593-4. PubMed ID: 15937465 [No Abstract] [Full Text] [Related]
9. Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk. Martinez DR; Vandergrift N; Douglas AO; McGuire E; Bainbridge J; Nicely NI; Montefiori DC; Tomaras GD; Fouda GG; Permar SR J Virol; 2017 May; 91(9):. PubMed ID: 28202762 [TBL] [Abstract][Full Text] [Related]
10. Short Communication: Exploring Antibody Potential as Prophylactic/Therapeutic Strategies for Prevention of Early Mucosal HIV-1 Infection. Su B; Peressin M; Ducloy C; Penichon J; Mayr LM; Laumond G; Schmidt S; Decoville T; Moog C AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1187-91. PubMed ID: 26252799 [TBL] [Abstract][Full Text] [Related]
11. Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. Burton DR; Hangartner L Annu Rev Immunol; 2016 May; 34():635-59. PubMed ID: 27168247 [TBL] [Abstract][Full Text] [Related]
12. The role of neutralizing antibodies in HIV infection. Humbert M; Dietrich U AIDS Rev; 2006; 8(2):51-9. PubMed ID: 16848273 [TBL] [Abstract][Full Text] [Related]
14. Immunology. Close to the edge: neutralizing the HIV-1 envelope. Nabel GJ Science; 2005 Jun; 308(5730):1878-9. PubMed ID: 15976295 [No Abstract] [Full Text] [Related]
15. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design. Sadanand S; Suscovich TJ; Alter G Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674 [TBL] [Abstract][Full Text] [Related]
16. Progress in HIV-1 antibody research using humanized mice. Gruell H; Klein F Curr Opin HIV AIDS; 2017 May; 12(3):285-293. PubMed ID: 28422792 [TBL] [Abstract][Full Text] [Related]
17. Neutralizing Antibody-Based Prevention of Cell-Associated HIV-1 Infection. Parsons MS; Le Grand R; Kent SJ Viruses; 2018 Jun; 10(6):. PubMed ID: 29912167 [TBL] [Abstract][Full Text] [Related]
18. HIV: Efficacy through BibNAbs. Flemming A Nat Rev Drug Discov; 2013 Sep; 12(9):666. PubMed ID: 23989794 [No Abstract] [Full Text] [Related]
19. HIV Vaccines: One Step Closer. Low MSY; Tarlinton D Trends Mol Med; 2017 Jan; 23(1):1-3. PubMed ID: 27889424 [TBL] [Abstract][Full Text] [Related]